Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics Inc. have inked a global development and commercialization deal worth up to $1.7 billion for Protagonist’s rusfertide for treatment of polycythemia vera (PV), a rare and chronic blood disorder affecting bone marrow. Read More
In a historic first, the U.S. Centers for Medicare & Medicaid Services (CMS) sent out its opening offers Feb. 1 for the first round of prescription drug price negotiations. Read More
Kiora Pharmaceuticals Inc.’s development and commercialization deal with Théa Open Innovation (TOI), a sister company of Laboratoires Théa, for KIO-301 in degenerative retinal diseases “takes a bit of an industry-standard type of approach” in terms of structure, said CEO Brian Strem. Read More
The U.S. FDA cleared an IND for Neurobo Pharmaceuticals Inc.’s weight loss drug, prompting the company to say a phase I study in obesity will begin sometime during the first half of this year. The stock catapulted upward on the news. Read More
The U.S. Federal Trade Commission (FTC) has drawn blistering criticism over the past couple of years over its handling of merger and acquisition (M&A) activity, criticism that was anything but blunted in a Jan. 31 webinar on the subject. Read More
New hires and promotions in the biopharma industry, including: Acumen, Enterobiotix, Maxion, Nextpoint, Onechain, Opthea, Proniras, Remix, Sanofi, Takeda, Verona. Read More
Biopharmas raising money in public or private financings, including: 60 Degrees, Aptose, Basking, Evaxion, Kyverna, Limmatech, Neophore, Panbela, Proniras, Revelation and Revive. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aneurotech, Inflectis, Metriopharm, Mycovia, Outlook, Rion. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acurastem, Alexion, Astellas, Catamaran, Clearmind, Dermtech, Gio, Graviton, Infinity, Novartis, Novavax, Obseva, Orange, Revive, Rgenta, Roche, Sanofi, Windtree. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 23andme, Astellas, Biontech, Cel-Sci, Daré, Defender, Duality, Ensysce, Jaguar Gene Therapy, Janssen, Vanda. Read More
